» Articles » PMID: 37371125

Human Adult Renal Progenitor Cells Prevent Cisplatin-Nephrotoxicity by Inducing CYP1B1 Overexpression and MiR-27b-3p Down-Regulation Through Extracellular Vesicles

Abstract

Cisplatin is one of the most effective chemotherapeutic agents strongly associated with nephrotoxicity. Tubular adult renal progenitor cells (tARPC) can regenerate functional tubules and participate in the repair processes after cisplatin exposition. This study investigated the molecular mechanisms underlying the protective effect of tARPC on renal epithelium during cisplatin nephrotoxicity. By performing a whole-genome transcriptomic analysis, we found that tARPC, in presence of cisplatin, can strongly influence the gene expression of renal proximal tubular cell [RPTEC] by inducing overexpression of CYP1B1, a member of the cytochrome P450 superfamily capable of metabolizing cisplatin and of hypoxia/cancer-related lncRNAs as MIR210HG and LINC00511. Particularly, tARPC exerted renoprotection and regeneration effects via extracellular vesicles (EV) enriched with CYP1B1 and miR-27b-3p, a well-known CYP1B1 regulatory miRNA. The expression of CYP1B1 by tARPC was confirmed by analyzing biopsies of cisplatin-treated renal carcinoma patients that showed the colocalization of CYP1B1 with the tARPC marker CD133. CYP1B1 was also overexpressed in urinary EV purified from oncologic patients that presented nephrotoxicity episodes after cisplatin treatment. Interestingly CYP1B1 expression significantly correlated with creatinine and eGFR levels. Taken together, our results show that tARPC are able to counteract cisplatin-induced nephrotoxicity via CYP1B1 release through EV. These findings provide a promising therapeutic strategy for nephrotoxicity risk assessment that could be related to abundance of renal progenitors.

Citing Articles

Effect of Long-Term Cisplatin Exposure on the Proliferative Potential of Immortalized Renal Progenitor Cells.

Ighofose E, Garrett S, Al-Marsoummi S, Mehus A, Sens D, Singhal S Int J Mol Sci. 2024; 25(23).

PMID: 39684265 PMC: 11640886. DOI: 10.3390/ijms252312553.


Platinum-based chemotherapies-induced nephrotoxicity: mechanisms, potential treatments, and management.

Shahrahmani F, Badamchizadeh S, Kaihani F, Alavi-Moghadam S, Keshtkari S, Rezaei-Tavirani M Int Urol Nephrol. 2024; .

PMID: 39630371 DOI: 10.1007/s11255-024-04303-2.


Extracellular vesicles for the treatment of ulcerative colitis: A systematic review and meta-analysis of animal studies.

Li Y, Yu Z, Zhang D, Zhang F, Zhang D, Chen M Heliyon. 2024; 10(17):e36890.

PMID: 39281542 PMC: 11400994. DOI: 10.1016/j.heliyon.2024.e36890.


Exosomal AC068768.1 enhances the proliferation, migration, and invasion of laryngeal squamous cell carcinoma through miR-139-5p/NOTCH1 axis.

Chen H, Gong X, Shen W, Zhu Z, Chen X Heliyon. 2024; 10(16):e36358.

PMID: 39258189 PMC: 11386030. DOI: 10.1016/j.heliyon.2024.e36358.

References
1.
Tang Z, Li C, Kang B, Gao G, Li C, Zhang Z . GEPIA: a web server for cancer and normal gene expression profiling and interactive analyses. Nucleic Acids Res. 2017; 45(W1):W98-W102. PMC: 5570223. DOI: 10.1093/nar/gkx247. View

2.
Chen P, Wang S, Cao C, Ye W, Wang M, Zhou C . α-naphthoflavone-derived cytochrome P450 (CYP)1B1 degraders specific for sensitizing CYP1B1-mediated drug resistance to prostate cancer DU145: Structure activity relationship. Bioorg Chem. 2021; 116:105295. DOI: 10.1016/j.bioorg.2021.105295. View

3.
McSweeney K, Kate Gadanec L, Qaradakhi T, Ali B, Zulli A, Apostolopoulos V . Mechanisms of Cisplatin-Induced Acute Kidney Injury: Pathological Mechanisms, Pharmacological Interventions, and Genetic Mitigations. Cancers (Basel). 2021; 13(7). PMC: 8036620. DOI: 10.3390/cancers13071572. View

4.
Elfaki I, Mir R, Almutairi F, Duhier F . Cytochrome P450: Polymorphisms and Roles in Cancer, Diabetes and Atherosclerosis. Asian Pac J Cancer Prev. 2018; 19(8):2057-2070. PMC: 6171375. DOI: 10.22034/APJCP.2018.19.8.2057. View

5.
Zhu Z, Mu Y, Qi C, Wang J, Xi G, Guo J . CYP1B1 enhances the resistance of epithelial ovarian cancer cells to paclitaxel in vivo and in vitro. Int J Mol Med. 2014; 35(2):340-8. PMC: 4292762. DOI: 10.3892/ijmm.2014.2041. View